APA (7th ed.) Citation

Fujimoto, N., Kozuki, T., Aoe, K., Miyamoto, Y., Wada, S., Harada, D., . . . Hotta, K. (2020). 1898P A phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma: JME-001. Annals of Oncology, 31, S1077. https://doi.org/10.1016/j.annonc.2020.08.1441

Chicago Style (17th ed.) Citation

Fujimoto, N., T. Kozuki, K. Aoe, Y. Miyamoto, S. Wada, D. Harada, M. Yoshida, J. Sakurai, and K. Hotta. "1898P A Phase II Trial of First-line Combination Chemotherapy with Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: JME-001." Annals of Oncology 31 (2020): S1077. https://doi.org/10.1016/j.annonc.2020.08.1441.

MLA (9th ed.) Citation

Fujimoto, N., et al. "1898P A Phase II Trial of First-line Combination Chemotherapy with Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: JME-001." Annals of Oncology, vol. 31, 2020, p. S1077, https://doi.org/10.1016/j.annonc.2020.08.1441.